Published in World J Gastroenterol on November 21, 2012
Radical excision of Barrett's esophagus and complete recovery of normal squamous epithelium. World J Gastroenterol (2013) 0.75
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 5.40
Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst (2011) 4.31
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol (2001) 4.16
Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol (2002) 3.94
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90
Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut (2000) 3.83
The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology (2006) 3.80
In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol (2006) 3.69
Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc (2007) 3.53
A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology (2004) 3.50
Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc (2009) 3.46
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Barrett's esophagus. Gastroenterology (2002) 3.27
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc (2007) 3.23
Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol (2004) 3.15
Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc (2008) 3.13
ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc (2006) 3.12
Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy (2010) 3.12
Gastro-oesophageal reflux disease. Lancet (2006) 2.96
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology (2002) 2.88
The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc (2006) 2.71
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol (2000) 2.58
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (2011) 2.51
Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc (2011) 2.51
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Barrett's metaplasia. Lancet (2000) 2.47
Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology (2001) 2.34
Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology (2001) 2.30
Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut (1991) 2.29
Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc (2010) 2.28
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology (2011) 2.27
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21
High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study. Endoscopy (2005) 2.21
Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut (2008) 2.20
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst (2002) 2.13
Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am (1997) 2.13
Endotherapy for Barrett's esophagus. Am J Gastroenterol (2012) 2.12
Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus. Endoscopy (2010) 2.11
Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg (2003) 2.03
Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther (1993) 1.96
Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut (2004) 1.92
Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy (2010) 1.83
Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. Gastrointest Endosc (2011) 1.82
Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol (2009) 1.76
In vivo histopathology for detection of gastrointestinal neoplasia with a portable, confocal miniprobe: an examiner blinded analysis. Clin Gastroenterol Hepatol (2007) 1.74
Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg (2008) 1.73
Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol (2003) 1.73
Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol (2006) 1.71
A pilot study of endoscopic spray cryotherapy by pressurized carbon dioxide gas for Barrett's esophagus. Endoscopy (2011) 1.70
Preliminary accuracy and interobserver agreement for the detection of intraepithelial neoplasia in Barrett's esophagus with probe-based confocal laser endomicroscopy. Gastrointest Endosc (2010) 1.69
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg (2000) 1.63
Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol (1998) 1.58
Confocal laser endomicroscopy in the "in vivo" histological diagnosis of the gastrointestinal tract. World J Gastroenterol (2009) 1.56
Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. Gastrointest Endosc (2004) 1.56
Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol (2000) 1.56
Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma. Am J Gastroenterol (2012) 1.54
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 1.54
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol (2011) 1.50
Columnar-lined oesophagus without intestinal metaplasia: results from a cohort with a mean follow-up of 7 years. Aliment Pharmacol Ther (2012) 1.48
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc (2009) 1.44
Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis. Endoscopy (2010) 1.44
Detection of intestinal metaplasia after successful eradication of Barrett's Esophagus with radiofrequency ablation. Dig Dis Sci (2011) 1.36
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol (2011) 1.36
Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc (2010) 1.27
Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2011) 1.23
Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut (1999) 1.18
Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc (2005) 1.15
Observer agreement in the assessment of narrowband imaging system surface patterns in Barrett's esophagus: a multicenter study. Endoscopy (2011) 1.13
The role of radiofrequency ablation in the management of Barrett's esophagus. Gastrointest Endosc Clin N Am (2011) 1.11
Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation. Gut (2001) 1.10
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
Confocal laser scanning fluorescence microscopy for in vivo determination of microvessel density in Barrett's esophagus. Endoscopy (2008) 1.09
Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.03
Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2012) 1.02
Barrett's esophagus and esophageal cancer: an overview. Int J Oncol (2012) 0.99
Cryotherapy for Barrett's esophagus and esophageal cancer. Curr Opin Gastroenterol (2011) 0.97
Hiatal hernia and the risk of Barrett's esophagus. J Gastroenterol Hepatol (2013) 0.97
How to manage a Barrett's esophagus patient with low-grade dysplasia. Clin Gastroenterol Hepatol (2008) 0.97
Photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am (2003) 0.96
The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther (2011) 0.95
Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther (1999) 0.95
Confocal laser endomicroscopy: potential in the management of Barrett's esophagus. Dis Esophagus (2010) 0.95
Cryotherapy for Barrett's esophagus: Who, how, and why? Gastrointest Endosc Clin N Am (2011) 0.95
Helpfulness of the combination of acetic acid and FICE in the detection of Barrett's epithelium and Barrett's associated neoplasias. World J Gastroenterol (2012) 0.94
Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett's esophagus. Gastrointest Endosc (2012) 0.93
The problems with surveillance of Barrett's esophagus. N Engl J Med (2011) 0.92
Magnification endoscopy and chromoendoscopy in evaluation of specialized intestinal metaplasia in Barrett's Esophagus. Dig Dis Sci (2011) 0.91